Antibiotic resistance often feels like a game of chess where bacteria always win the next move. But evolutionary trade-offs show us that the board is not tilted entirely against us. When bacteria evolve resistance to one drug, they sometimes expose new weaknesses — a phenomenon called collateral sensitivity. This flips the narrative from checkmate to counter-play.
Collateral sensitivity occurs when a mutation that protects bacteria against one antibiotic makes them more vulnerable to another. Efflux pump mutations that eject aminoglycosides can inadvertently allow beta-lactams to penetrate more easily, creating a broad, predictable weakness across resistant populations. Clinically, this trade-off is exploitable.
Not all evolutionary trade-offs benefit us. Sometimes, resistance to one antibiotic also confers resistance to another. Ribosomal mutations, for example, can block multiple protein-synthesis inhibitors simultaneously.
Clinical tactics
Combination therapy: prescribing two drugs with reciprocal weaknesses together, leaving bacteria with no safe genetic escape route.
Drug cycling: switching treatments at the moment resistance emerges, catching bacteria off-guard when they are most vulnerable.
The promise of collateral sensitivity depends on surveillance. By turning evolutionary science into practical strategy, collateral sensitivity transforms bacterial adaptation from our greatest threat into our sharpest weapon.